Anne Li March 25th, 2017
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK. The investment will support the PRECISION Panc* project which aims to develop personalised treatments for pancreatic cancer patients, improving the options and outcomes for a disease where survival rates have remained stubbornly low. Professor Andrew Biankin at the University of Glasgow, who has pioneered the project along with researchers across the UK, aims to speed up recruitment and enrolment of pancreatic cancer patients to clinical trials that are right for the individual patient. The researchers will use the molecular profile of each individual cancer to offer patients and their doctor a menu of trials that might benefit them.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-03-24-new-era-in-precision-medicine-for-pancreatic-cancer